These include local (adipose tissue) and systemic inflammation (as assessed by an increase in the circulating inflammatory marker SAA), dyslipidemia, insulin resistance and mild elevations in fasting glucose levels [32]. This evidence concerns the gene SAA2 and metabolic syndrome.